2024 PACC Miami | Clinical Review of Tarlatamab-dlle, The First Bispecific T-Cell Engager (BiTE) Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer
0% Complete
Course Overview
NA
Course Content
Course Details
- Duration
- 0.00 hour
- Released
- May 14, 2025
- Last Review
- May 14, 2025
- Expires
- May 14, 2028
Objectives
NA
Target Audience
NA
Faculty & Disclosure
Faculty
Khurrum Qureshi, PharmD, BCOP
Disclosure
Khurrum Qureshi, PharmD, BCOP discloses no such relationships exist
Accreditation
NA
Related Courses
2025 SPS Puerto Rico | Infliximab Intravenous vs. Subcutaneous: Clinical and Practice Considerations
0.00 AMA PRA Category 1 Credits™
1 Chapter
Pharmacological
Free
2025 SPS Puerto Rico | An Expanding Bispecifics Armamentarium: Zanidatamab Clinical Review and Considerations
0.00 AMA PRA Category 1 Credits™
1 Chapter
Pharmacological
Free